These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 3627540)

  • 1. [Blood coagulation tests and oral contraceptives].
    Scalettaris U; Bertolini C; Michelon C
    Minerva Ginecol; 1987 May; 39(5):325-7. PubMed ID: 3627540
    [No Abstract]   [Full Text] [Related]  

  • 2. [A new test system for evaluating the risk of thromboembolism in the use of hormonal contraceptives].
    Pechlaner C; Kunz F; Tabarelli M; Sölder E; Zwierzina WD; Reitsamer R; Koch R
    Gynakol Rundsch; 1989; 29 Suppl 2():312-4. PubMed ID: 2613036
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study.
    Middeldorp S; Meijers JC; van den Ende AE; van Enk A; Bouma BN; Tans G; Rosing J; Prins MH; Büller HR
    Thromb Haemost; 2000 Jul; 84(1):4-8. PubMed ID: 10928461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Surveillance of women taking oral contraceptives by determination of antithrombin III].
    Benoit MO; Raichvarg D; Caillens H; Neau C
    Nouv Presse Med; 1979 Feb; 8(7):528-9. PubMed ID: 461171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Changes in blood coagulation during hormonal contraception].
    von Hugo R; Lenz A; Hafter R
    Gynakol Rundsch; 1985; 25 Suppl 2():138-41. PubMed ID: 4093018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral contraceptives and hypercoagulation.
    Petitti DB
    Clin Adv Hematol Oncol; 2006 Nov; 4(11):813-5. PubMed ID: 17143250
    [No Abstract]   [Full Text] [Related]  

  • 7. [APC (activated protein C) resistance and oral contraceptives].
    Kreis I; Weiss T; Rabe TN; Ziegler R; Nawroth PP
    Geburtshilfe Frauenheilkd; 1996 May; 56(5):231-3. PubMed ID: 8768059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Contraceptive agents and risk of thrombosis].
    Maurer-Major E; Keller PJ
    Praxis (Bern 1994); 1997 Oct; 86(40):1543-8. PubMed ID: 9417570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The routine coagulation tests along with activated protein C resistance (APC-R) in population of women applying for oral contraceptives].
    Kostecka I; Dabrowska M; Osada J; Suchowierska M; Wołczyński S
    Przegl Lek; 2001; 58(12):1038-40. PubMed ID: 12041017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term and long-term intra-individual variations and critical differences of coagulation parameters.
    Costongs GM; Bas BM; Janson PC; Hermans J; Brombacher PJ; van Wersch JW
    J Clin Chem Clin Biochem; 1985 Jul; 23(7):405-10. PubMed ID: 4045388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Antithrombin III during pregnancy and puerperium (author's transl)].
    Torner C; Leroy B; Fouche F; Perles R
    Nouv Presse Med; 1979 Jan; 8(1):46. PubMed ID: 554062
    [No Abstract]   [Full Text] [Related]  

  • 12. Oral contraception and thrombophilia.
    Blickstein D; Blickstein I
    Curr Opin Obstet Gynecol; 2007 Aug; 19(4):370-6. PubMed ID: 17625421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral contraceptives and venous thromboembolism.
    Savage RL
    N Z Med J; 1997 Mar; 110(1040):109. PubMed ID: 9137318
    [No Abstract]   [Full Text] [Related]  

  • 14. [Hormonal contraceptive agents as a risk factor in the development of acute thromboembolic diseases].
    Lambrekht R; Vageman V; Vinkelman B; Geĭnrikh P
    Khirurgiia (Mosk); 1986 Dec; (12):90-3. PubMed ID: 3821001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular disease and steroid hormone contraception. Report of a WHO Scientific Group.
    World Health Organ Tech Rep Ser; 1998; 877():i-vii, 1-89. PubMed ID: 9615606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in haemostatic variables induced by oral contraceptives containing 50 micrograms or 30 micrograms oestrogen: absence of dose-dependent effect on PAI-1 activity.
    Scarabin PY; Plu-Bureau G; Zitoun D; Bara L; Guize L; Samama MM
    Thromb Haemost; 1995 Sep; 74(3):928-32. PubMed ID: 8571323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hormonal contraception and risk of venous thromboembolism: When to ask for an assessment of hemostasis? Which parameters?].
    Plu-Bureau G; Horellou MH; Gompel A; Conard J
    Gynecol Obstet Fertil; 2008 Apr; 36(4):448-54. PubMed ID: 18424163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives.
    Quehenberger P; Loner U; Kapiotis S; Handler S; Schneider B; Huber J; Speiser W
    Thromb Haemost; 1996 Nov; 76(5):729-34. PubMed ID: 8950781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What is the risk of venous thromboembolism (VTE) among women taking third-generation oral contraceptives (OCs) in comparison with those taking contraceptives containing levonorgestrel?
    Meurer LN; Slawson JG
    J Fam Pract; 2001 Feb; 50(2):108. PubMed ID: 11219554
    [No Abstract]   [Full Text] [Related]  

  • 20. [Real and false risks of hormonal contraceptives].
    Belaïsch J
    Gynakol Rundsch; 1984; 24 Suppl 1():12-9. PubMed ID: 6519541
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.